FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 350 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Leveraging Extensive Real-World Data to Systematically Identify Mutations that Predict the... July 11, 2022 Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies March 17, 2023 Extended Follow-Up Further Supports Lenvatinib Plus Pembrolizumab in Patients with Previously... April 20, 2023 How Exercise Can Help You Cope With the Mental and Emotional... August 18, 2022 Load more HOT NEWS New on NCI’s Websites for September 2020 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... COVID Vaccine Basics for Cancer Patients Interactive App Improves Colorectal Cancer Screening Rates
